Company Profile

Inson Medical Systems, Inc. was founded to apply the newest innovations in biomaterials to drug delivery solutions. The Inson Solution™ is a drug delivery platform derived from technology patented by the University of Washington Engineered Biomaterials Group. Despite advances in technology, oral drug delivery systems frequently are neither efficient nor safe routes-of-delivery for the majority of the newest more-potent medications. Transdermal patches and improved injection technology are two alternative methods for administration of new drugs. The disadvantage with these routes of administration is that the medication still needs to transverse the bloodstream and tissue barriers in order to reach the target site of action. Market analysts predict that the demand for new drug delivery systems will increase by over 10% annually to $132 billion in 2012.1,2 Of the competing delivery systems, non-oral routes-of-administration are expected to provide the strongest growth opportunities at 15% annual growth (vs. 7.1% for oral delivery technologies).1,2 A more elegant and efficient method of drug delivery has been developed by Inson Medical Systems, Inc. The Inson Solution™ is to implant a biocompatible drug bead directly at the target site. This proprietary Inson delivery device can deliver a drug in either a controlled continuous flow or in discrete doses on demand. The Inson Solution™ makes use of an innovative and patented “rate-limiting-barrier” technology that can be “grown” onto the surface of virtually all types of approved polymeric biomaterials. The result is a medical device that can deliver a constant dosage of medication over a time period ranging from 24 hours to 45 days, commonly known as zero-order release (ZOR) kinetics. The elegance of this design is that it allows Inson to craft small, soft, moldable drug depots that can be easily implanted. The Inson Solution™ makes it possible to place medication in sites that are too small for traditional on-site methods such as the interior of the eye, brain and spine. Currently, the ability to deliver distinct doses of medicine without the repetitive use of needles is limited to transdermal patches, catheters, controlled-release polymers or implantable electronic devices. The implantable electronic devices come the closest to providing a secure, on-demand form of release, but they are large, difficult to locate and implant and should any component fail, surgery is immediately required. In contrast, The Inson Solution™ only requires that a small polymeric bead be implanted. Inson is also licensing a more stringent SAM formulation which completely blocks all drug release until an external stimulus is applied via ultrasound, a Secure On-Demand Release (SODR) formulation. Due to its unique nature and its applicability with multiple drug candidates, many of the most lucrative medical markets have a need for the SODR technology including the diabetes, obesity, cancer (particularly brain tumors), and pain markets. Because the SODR technology is more complicated needing multiple components to be developed (the bead itself, the ultrasound applicator, and a device to insert and remove the beads), Inson’s current plan is to first build its business reputation and revenue stream with the faster-to-mar